Regeneron

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. Founded in 1988, it is engaged in the discovery, development, manufacturing, and commercialization of scientifically advanced human medicines. The company's focus is on a range of therapeutic areas, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular diseases, infectious diseases, and rare diseases.

Regeneron utilizes its proprietary VelocImmune technology, a genetic engineering method that enables the rapid generation of fully human antibodies. This technology has been central to the company's success in developing innovative treatments. Key products include EYLEA (aflibercept) for eye diseases like wet age-related macular degeneration and diabetic macular edema, and Dupixent (dupilumab), a treatment for moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.

The company has a strong pipeline of investigational drugs, with ongoing research and development across various disease areas. Regeneron collaborates with other pharmaceutical companies, notably Sanofi and Bayer, on the development and commercialization of some of its therapies. Its scientific approach emphasizes a deep understanding of biology to create breakthrough medicines for patients with serious unmet medical needs.